{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:02:27Z","timestamp":1793347347856,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Elios Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00262-022-03272-8","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T03:31:37Z","timestamp":1662003097000},"page":"697-705","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial"],"prefix":"10.1007","volume":"72","author":[{"given":"Alexandra M.","family":"Adams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth L.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy T.","family":"Clifton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Vreeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Chick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E.","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip M.","family":"Kemp Bohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies T.","family":"Hickerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin A.","family":"Valdera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane F.","family":"Hale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Hyngstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Jakub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Sussman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montaser F.","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark B.","family":"Faries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Peoples","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"issue":"3","key":"3272_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.clindermatol.2012.08.012","volume":"31","author":"D Davar","year":"2013","unstructured":"Davar D, Tarhini AA, Kirkwood JM (2013) Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach. Clin Dermatol 31(3):237\u2013250. https:\/\/doi.org\/10.1016\/j.clindermatol.2012.08.012","journal-title":"Clin Dermatol"},{"issue":"1","key":"3272_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrclinonc.2013.208","volume":"11","author":"CG Drake","year":"2013","unstructured":"Drake CG, Lipson EJ, Brahmer JR (2013) Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 11(1):24\u201337. https:\/\/doi.org\/10.1038\/nrclinonc.2013.208","journal-title":"Nat Rev Clin Oncol"},{"key":"3272_CR3","first-page":"1","volume":"1","author":"JA Marin-Acevedo","year":"2018","unstructured":"Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y (2018) Cancer immunotherapy beyond immune checkpoint inhibitors. J hematol oncol 1:1\u201325","journal-title":"J hematol oncol"},{"issue":"12","key":"3272_CR4","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1080\/1744666X.2016.1202114","volume":"12","author":"TJ Vreeland","year":"2016","unstructured":"Vreeland TJ et al (2016) Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines (in eng). Expert Rev Clin Immunol 12(12):1347\u20131357","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"3272_CR5","first-page":"201","volume":"12","author":"J Kleponis","year":"2015","unstructured":"Kleponis J, Skelton R, Zheng L (2015) Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biol Med 12(3):201\u2013208","journal-title":"Cancer Biol Med"},{"issue":"7","key":"3272_CR6","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.4161\/onci.20591","volume":"1","author":"RA Madan","year":"2014","unstructured":"Madan RA, Heery CR, Gulley JL (2014) Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity. OncoImmunology 1(7):1167\u20131168","journal-title":"OncoImmunology"},{"issue":"7","key":"3272_CR7","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","volume":"15","author":"S Anguille","year":"2014","unstructured":"Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN (2014) \u201cClinical use of dendritic cells for cancer therapy,\u201d (in eng). Lancet Oncol 15(7):e257\u2013e267","journal-title":"Lancet Oncol"},{"issue":"5","key":"3272_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411\u2013422. https:\/\/doi.org\/10.1056\/NEJMoa1001294","journal-title":"N Engl J Med"},{"issue":"23","key":"3272_CR9","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1200\/jco.2000.18.23.3894","volume":"18","author":"EJ Small","year":"2000","unstructured":"Small EJ et al (2000) Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18(23):3894\u20133903. https:\/\/doi.org\/10.1200\/jco.2000.18.23.3894","journal-title":"J Clin Oncol"},{"issue":"23","key":"3272_CR10","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1016\/j.vaccine.2018.04.078","volume":"36","author":"GS Herbert","year":"2018","unstructured":"Herbert GS et al (2018) \u201cInitial phase I\/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors,\u201d (in eng). Vaccine 36(23):3247\u20133253. https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.078","journal-title":"Vaccine"},{"key":"3272_CR11","doi-asserted-by":"publisher","first-page":"6126","DOI":"10.1245\/s10434-021-09709-1","volume":"11","author":"TJ Vreeland","year":"2021","unstructured":"Vreeland TJ, Clifton GT, Hale DF, Chick RC, Hickerson AT, Cindass JL, Adams AM, Bohan PM, Andtbacka RH, Berger AC, Jakub JW (2021) A phase IIb randomized controlled trial of the TLPLDC vaccine as adjuvant therapy after surgical resection of Stage III\/IV Melanoma: a primary analysis. Annal surg oncol 11:6126\u20136137. https:\/\/doi.org\/10.1245\/s10434-021-09709-1","journal-title":"Annal surg oncol"},{"issue":"3","key":"3272_CR12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nri.2017.131","volume":"18","author":"Z Hu","year":"2018","unstructured":"Hu Z, Ott PA, Wu CJ (2018) Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol 18(3):168\u2013182","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"3272_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/14760584.2018.1434000","volume":"17","author":"WS Bowen","year":"2018","unstructured":"Bowen WS, Svrivastava AK, Batra L, Barsoumian H, Shirwan H (2018) Current challenges for cancer vaccine adjuvant development. Expert Rev Vaccines 17(3):207\u2013215","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"3272_CR14","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/CMR.0000000000000758","volume":"31","author":"AM Adams","year":"2021","unstructured":"Adams AM, Chick RC, Vreeland TJ, Clifton GT, Hale DF, McCarthy PM, O\u2019Shea AE, Bohan PM, Hickerson AT, Park H, Sloan AJ (2021) Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma. Melanoma res 31(4):378\u2013388","journal-title":"Melanoma res"},{"issue":"1","key":"3272_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin M (2011) Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet j 17(1):10\u201312","journal-title":"EMBnet j"},{"key":"3272_CR16","unstructured":"S. Andrews, \"FastQC: a quality control tool for high throughput sequence data.,\" 2010."},{"issue":"1","key":"3272_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A et al (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29(1):15\u201321. https:\/\/doi.org\/10.1093\/bioinformatics\/bts635","journal-title":"Bioinformatics"},{"issue":"2","key":"3272_CR18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2014","unstructured":"Anders S, Pyl PT, Huber W (2014) HTSeq\u2013a Python framework to work with high-throughput sequencing data. Bioinformatics 31(2):166\u2013169. https:\/\/doi.org\/10.1093\/bioinformatics\/btu638","journal-title":"Bioinformatics"},{"key":"3272_CR19","first-page":"1","volume":"12","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Gen biol 12:1\u201321","journal-title":"Gen biol"},{"issue":"16","key":"3272_CR20","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1093\/bioinformatics\/bts356","volume":"28","author":"L Wang","year":"2012","unstructured":"Wang L, Wang S, Li W (2012) RSeQC: quality control of RNA-seq experiments. Bioinformatics 28(16):2184\u20132185. https:\/\/doi.org\/10.1093\/bioinformatics\/bts356","journal-title":"Bioinformatics"},{"issue":"7","key":"3272_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s004030000144","volume":"292","author":"H Jonuleit","year":"2000","unstructured":"Jonuleit H, Giesecke A, Kandemir A, Paragnik L, Knop J, Enk AH (2000) Induction of tumor peptide-specific cytotoxic T cells under serum-free conditions by mature human dendritic cells. Arch dermatol res 292(7):325\u201332","journal-title":"Arch dermatol res"},{"issue":"2","key":"3272_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/ijc.1323","volume":"93","author":"H Jonuleit","year":"2001","unstructured":"Jonuleit H et al (2001) A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 93(2):243\u2013251. https:\/\/doi.org\/10.1002\/ijc.1323","journal-title":"Int J Cancer"},{"issue":"4","key":"3272_CR23","doi-asserted-by":"publisher","first-page":"e18801","DOI":"10.1371\/journal.pone.0018801","volume":"6","author":"A Draube","year":"2011","unstructured":"Draube A, Klein-Gonzalez N, Mattheus S, Brillant C, Hellmich M, Engert A, von Bergwelt-Baildon M (2011) Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS ONE 6(4):e18801","journal-title":"PLoS ONE"},{"issue":"4","key":"3272_CR24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ajh.20010","volume":"75","author":"H Suzuki","year":"2004","unstructured":"Suzuki H et al (2004) \u201cActivities of granulocyte-macrophage colony-stimulating factor and interleukin-3 on monocytes,\u201d (in eng). Am J Hematol 75(4):179\u2013189","journal-title":"Am J Hematol"},{"key":"3272_CR25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1251\/bpo62","volume":"5","author":"B Obermaier","year":"2003","unstructured":"Obermaier B, Dauer M, Herten J, Schad K, Endres S, Eigler A (2003) \u201cDevelopment of a new protocol for 2-day generation of mature dendritic cells from human monocytes,\u201d (in eng). Biol Proced Online 5:197\u2013203. https:\/\/doi.org\/10.1251\/bpo62","journal-title":"Biol Proced Online"},{"issue":"4","key":"3272_CR26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3390\/biomedicines3040282","volume":"3","author":"SP Sittig","year":"2015","unstructured":"Sittig SP, de Vries IJM, Schreibelt G (2015) Primary Human Blood Dendritic Cells for Cancer Immunotherapy-Tailoring the Immune Response by Dendritic Cell Maturation. Biomedicines 3(4):282\u2013303. https:\/\/doi.org\/10.3390\/biomedicines3040282","journal-title":"Biomedicines"},{"issue":"1","key":"3272_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.0105-2896.2009.00881.x","volume":"234","author":"M Swiecki","year":"2010","unstructured":"Swiecki M, Colonna M (2010) Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev 234(1):142\u2013162. https:\/\/doi.org\/10.1111\/j.0105-2896.2009.00881.x","journal-title":"Immunol Rev"},{"issue":"1","key":"3272_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1006\/cimm.2001.1883","volume":"214","author":"Z Chen","year":"2001","unstructured":"Chen Z et al (2001) DNA array and biological characterization of the impact of the maturation status of mouse dendritic cells on their phenotype and antitumor vaccination efficacy. Cell Immunol 214(1):60\u201371. https:\/\/doi.org\/10.1006\/cimm.2001.1883","journal-title":"Cell Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03272-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03272-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03272-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:55:14Z","timestamp":1744206914000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03272-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["3272"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03272-8","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"assertion":[{"value":"7 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the Western Institutional Review Board and all patients provided informed consent for participation. Dr. Faries is an advisor for Bristol-Myers Squibb, Sanofi, Array Bioscience and Pulse Bioscience. Dr. Wagner is an employee of Orbis Health Solutions. Dr. Peoples is employed by Orbis Health Solutions and Cancer Insight; is a consultant for Rapamycin Holdings, Heat Biologics, Abexxa Biologics, and Pelican Therapeutics; and has received funding from the above as well as Sellas Life Sciences and Genentech. Dr Jakub served on a Novartis Melanoma Surgical Oncology Advisory Board. Dr. Clifton is employed by Parthenon Therapeutics. The view(s) expressed herein are those of the author(s) and do not reflect the official policy or position of Brooke Army Medical Center, the US Army Medical Department, the Department of the Army, Department of the Air Force, Department of Defense, or the US Government. The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DODI 3216.02_AFI40-402.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}